Support The Moscow Times!

Rusnano in Medical Venture

LONDON — The Russian government has become the leading shareholder in a new drug company with a mission to develop nanotechnology, help the world's poor and list in London and Moscow within a few years.

Pro Bono Bio is formed from the assets of Celtic Pharma, a private equity group based in London, and Rusnano.

A company spokesman said Monday that Rusnano had already invested around £300 million ($477 million) in Celtic's funds and would have a stake of more than 40 percent in Pro Bono Bio.

Pro Bono Bio has a commitment to price its products in different countries based on their ability to pay and donate free drugs to Africa based on sales of products at normal prices in Western Europe.


Read more

Independent journalism isn’t dead. You can help keep it alive.

The Moscow Times’ team of journalists has been first with the big stories on the coronavirus crisis in Russia since day one. Our exclusives and on-the-ground reporting are being read and shared by many high-profile journalists.

We wouldn’t be able to produce this crucial journalism without the support of our loyal readers. Please consider making a donation to The Moscow Times to help us continue covering this historic time in the world’s largest country.